Table 2. Demographic and clinical data of IPA and non-IPA patients.
| Patients with IPA (n = 57) | Patients without IPA (n = 125) | ‡ P values | |
| Demographic variables | |||
| Age (range) | 48.98 (16-76) | 50.95 (16-78) | NS |
| Sex ratio (male/female) | 35/22 | 70/55 | NS |
| Hematological disease (%) | |||
| AML | 27 (47.37) | 41 (32.80) | |
| ALL | 9 (15.79) | 12 (9.60) | |
| MM | 4 (7.02) | 20 (16.00) | |
| CML | 0 (0.00) | 2 (1.60) | |
| HL | 2 (3.51) | 15 (12.00) | |
| NHL | 8 (14.03) | 23 (18.40) | |
| AA | 3 (5.26) | 2 (1.60) | |
| CLL | 2 (3.51) | 6 (4.80) | |
| MDS | 2 (3.51) | 4 (3.20) | |
| EORTC/MSG 2008 classification | |||
| Proven IPA | 13 (22.80) | - | |
| Probable IPA | 44 (77.20) | - | |
| Risk factors | |||
| HSCT | 33 (57.90) | 53 (42.4) | NS |
| Severe neutropenia† | 45 (78.95) | 105 (84.00) | NS |
| Corticoid therapy | 14 (24.56) | 40 (32.00) | NS |
| GVHD | 8 (14.04) | 11 (8.80) | NS |
Abbreviations: NS, non-significant. HSCT: Hematopoietic stem cell transplantation, AML: acute myeloid leukemia, ALL: acute lymphoid leukemia, MM: Multiple Myeloma, CML: chronic myeloid leukemia, HL: Hodgekin's lymphoma, NHL: non-Hodgekin's lymphoma, AA: Aplastic anemia, CLL: chronic lymphocytic leukemia, MDS: myelodysplastic syndrome.
†
: Severe neutropenia was defined as absolute neutrophil count <500 cells/mm3 for a period of more than 12 days. GVHD: graft versus host disease;
‡
: p-values were calculated by student-t test for continous- and Fishers exact test for binary data.